The Oregon Prescription Drug Affordability Board (PDAB) is reviewing high-cost drugs that may strain Oregon patients or our health care system. They want to hear your experience with high costs on ANY of the prescription drugs on their review list. Use the website below to share: bit.ly/or-pdab-comment
On August 20,
the Oregon PDAB will review: Trelegy* (Fluticasone furoate; Umeclidinum bromide; Vilanterol trifenatate)
Eliquis* (Apixaban)
Xarelto (Rivaroxaban)
Cosentyx (Secukinumab)
Creon (Pancrelipase [Amylase; Lipase; Protease])
* = No generic currently avaiable
PDAB Has Already Reviewed:
Vraylar* (Cariprazine HCl )
Entresto (Sacubitril; Valsartan)
Ajovy (Fremanezumab-vfrm)
Emgality (Galcanezumab-gnlm)
Nurtec (Rimegepant/ rimegepant sulfate)
Ubrelvy* (Ubrogepant)
*=no generic currently available
you can still share your story about these drugs until November 19
The #Oregon #PDAB is meeting to review: #Trelegy, #Eliquis, #Xarelto, #Cosentyx, & #Creon on Aug. 20 at 8 am!
If you or someone you know has taken any of these (or any others on their list), they need to hear from you! Send a letter/sign up to speak at bit.ly/or-pdab-comment